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ABSTRACT 
Hepatitis C virus (HCV) translation initiation depends on an internal ribosome entry site 
(IRES). We previously identified an RNA molecule (HH363-10) able to bind and cleave 
the HCV IRES region. This paper characterizes its capacity to interfere with IRES function. 
Inhibition assays showed that it blocks IRES activity both in vitro and in a human 
hepatoma cell line. Although nucleotides involved in binding and cleavage reside in 
separate regions of the inhibitor HH363-10, further analysis demonstrated the strongest 
effect to be an intrinsic feature of the entire molecule; the abolishment of any of the two 
activities resulted in a reduction in its function. Probing assays demonstrate that HH363-10 
specifically interacts with the conserved IIIf domain of the pseudoknot structure in the 
IRES, leading to the inhibition of the formation of translationally competent 80S particles. 
The combination of two inhibitory activities targeting different sequences in a chimeric 
molecule may be a good strategy to avoid the emergence of resistant viral variants.  
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INTRODUCTION 
 
Hepatitis C virus (HCV) infection affects more than 170 million people worldwide. 
Current treatments show poor efficacy due to the highly active dynamics of the HCV 
populations that promote the appearance of drug-resistant variants [1]. This problem, also 
faced in control of other viral infections, has prompted an intensive search for new drugs 
and alternative therapeutic strategies. Combination approaches are currently considered 
excellent candidates to reduce the chance of viral evasion.    
The HCV genome is a 9500 nucleotide-long (+) ssRNA molecule. During early viral 
infection, uncapped viral RNAs initiate their translation using a highly conserved internal 
ribosome entry site (IRES) located at the 5’ untranslated region (UTR; Fig. 1; [2, 3]), which 
includes from nt 40 to 372 of the viral genome [4, 5]. It has a complex secondary and 
tertiary structure that acts as a scaffold for recruiting multiple protein factors during the 
initiation of translation [6]. This mechanism considerably differs from that used by the 
cellular capped mRNAs, rendering it a potential candidate for antiviral therapies. 
The use of RNA molecules as gene inactivation agents is a therapeutic option that has 
been investigated in depth [7]. Antisense RNAs and siRNAs have been proved to 
effectively inhibit replication of several viruses, including HCV [8]. These molecules work 
by sequence complementarity and in many cases viruses promptly escape to the treatment 
[9-13]. Viral targeting with other RNA molecules like ribozymes and aptamers has also 
been accomplished with different success [8]. In contrast to antisense and siRNAs, 
aptamers do not operate only by sequence complementarity, but also by the recognition of 
secondary and tertiary structures. The formation of productive complexes is a major 
requisite for the correct functioning of aptamers and ribozymes too. These features 
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contribute to diminish the chance of appearance of resistant viral mutants. An additional 
issue to minimize the risk of the emergence of escape variants is the use of several 
inhibitors with different specificities [14-16]. We previously designed a novel combined 
approach [17]. An in vitro selection method was employed to isolate a collection of RNA 
molecules composed of a hammerhead ribozyme (named HH363) targeting positions 357-
369 of the HCV genome, plus an aptamer for the 5’UTR that carries a domain 
complementary to unique sequences in the IRES domain [17]. In this paper, the selected 
variants have been assayed for their ability to interfere with IRES function. This has 
allowed the identification of a very potent inhibitor designated as HH363-10, which 
behaves as an aptamer with complementary sequences to domain IIIf of the 5’UTR (Ap10; 
Fig. 1; [17]). This region participates in the formation of a pseudoknot structure essential 
for IRES function [18]. It has been proposed that the IIIf domain interacts with the 40S 
ribosomal subunit [19, 20] and favors the formation of active translational 80S complexes 
[21]. This paper is the first to report an RNA molecule that combine two functional 
modules that interact with different regions of the HCV IRES, interfering with its function 
both in vitro and in a human liver cell line.  
 
MATERIALS AND METHODS 
 
DNA templates and RNA synthesis 
All RNAs were synthesized by in vitro transcription and purified as previously described 
[22]. DNA templates for the HCV-derived RNAs 5’HCV-691 and 5’HCV-691gg were 
obtained as previously described [17]. The template for RNA 667 was derived from the 
pcDNA3 vector (Invitrogen) linearized with DraIII. The coding sequence for IRES-FLuc 
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was obtained by PCR amplification of the plasmid pCMVCatIREcLuc [17]. The pRLSV40 
vector (Promega) was linearized with BamH1 for the synthesis of RLuc mRNA.  
The DNA templates for the HH363-10 and HH363 inhibitory RNAs were obtained as 
described in [17]). The dsDNAs used for the synthesis of Ap10, HH363m-10, HH363-10m 
and HH363m-10m were generated by annealing and extension as previously described 
[23], of oligonucleotide T7GG (5’-taatacgactcactatagg-3’) with T7Ap10 (5’-
GTAGGATTACGAATCACTCAGAAcctatagtgagtcgtatta-3’), 5’T7HH363m (5’-
TAATACGACTCACTATAGGGTTCTTTCTGATAAGTCCGTgaggacgaaaggttt-3’) with 
asHH363-10 (5’-
GCTGAAAGCTTGGATCCGCTCAGTAGGATTACGAATCACTCAGAAaaacctttcgtcctc
-3’), 5’HH363is (5’-
TATGAATTCTAATACGACTCACTATAGGGTTCTTTCTGATGAGTCCGTgaggacgaaa
ggttt-3’) with asHH363-10m (5’-
GCTGAAAGCTTGGATCCGCTCAGTAGGATGTGCAATCACTCAGAAaaacctttcgtcctc
-3’), and 5’T7HH363m (5’-
TAATACGACTCACTATAGGGTTCTTTCTGATAAGTCCGTgaggacgaaaggttt-3’) with 
asHH363-10m (5’-
GCTGAAAGCTTGGATCCGCTCAGTAGGATGTGCAATCACTCAGAAaaacctttcgcctc-
3’; the T7 promoter sequence is underlined; lower case letters indicate the complementary 
sequences). The plasmid pBSSK was digested with the restriction enzyme BamH1 for the 
synthesis of RNA80. 
The RNA molecules employed in the inhibition assays were obtained using the 
RiboMAXTM-T7 large scale RNA production system (Promega); the manufacturer’s 
instructions were strictly followed. The transcription mix of IRES-FLuc was supplemented 
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with 200 µCi of α-32P-UTP for ribosome assembly assays. During the synthesis of the RNA 
RLuc, a cap structure was incorporated into its 5’ end by adding 5 mM of Ribo m7G Cap 
Analog (Promega). The resulting RNAs were purified by phenol extraction and 
unincorporated nucleotides were removed by two consecutive steps of size exclusion 
chromatography (Sephadex G-25, GE Healthcare). The RNA amount was determined by 
A260 measurements, and the extent of protein and carbohydrate/phenolic contaminations 
was assessed by A260/A280 and A260/A230 ratios, respectively. The integrity of the RNA was 
determined by agarose-formaldehyde gel electrophoresis.  
 
In vitro translation assays 
IRES-FLuc and RLuc mRNAs were translated using the Flexi® rabbit reticulocyte lysate 
system (Promega). Reactions proceeded in 6 µl volumes containing 4 µl of cell extract, 0.1 
µl of the provided aminoacid mixture lacking methionine (1mM), and 0.1 µl (1.5 µCi) of a 
mixture of L-(35S)-methionine and L-(35S)-cysteine (Redivue Pro-mix L-(35S) in vitro cell 
labeling kit, GE Healthcare). KCl was supplemented at 100 mM. The RNA templates for 
the synthesis of either FLuc (IRES-FLuc) or RLuc (RNA RLuc) proteins were added at a 
final concentration of 30 ng/µl (~ 40 nM) and 20 ng/µl (~ 60 nM) respectively. Inhibitory 
RNA concentrations ranging from 10 nM to 5 µM were assayed. All the RNA molecules 
were subjected to a denaturing step at 65ºC for 10 min and subsequently incubated at 4ºC 
for 15 min prior to their incorporation into the translation mix. Translation proceeded at 
30ºC for 60 min. Reactions were stopped on ice and the protein products resolved on 12.5% 
(w/v) denaturing polyacrylamide gels. Dried gels were scanned in a Phosphorimager 
(Storm 820, GE Healthcare) and quantified with Image Quant 5.2© software (GE 
Healthcare). The IC50 values were calculated with SigmaPlot 8.02© software using the 
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equation y = ymax/(1 + 10(LogIC50-X)), where ymax is the maximum percentage of FLuc relative 
synthesis, IC50 the inhibitor concentration that produces 50% of the maximum observed 
effect, and X the inhibitor concentration.  
 
IRES cleavage assays 
Cleavage experiments proceeded in the presence of RRL under in vitro translation 
reaction conditions. All were performed in the presence of 40 nM 32P-internally 
radiolabeled RNA substrate 5’HCV-691. Substrates and inhibitor RNAs were denatured 
and renatured as described above. After 60 min at 30ºC, reactions were stopped on ice and 
the RNA molecules were phenol-extracted. Cleavage products were resolved on 4% 
denaturing polyacrylamide gels, which were subsequently dried and analyzed as above. 
 
RNA-RNA interaction probing assays 
RNA probing assays of the complex HH363-10/IRES were performed with 32P 5’ end-
labeled inhibitor RNA. Complexes were constructed as described in [17] by incubating 50 
fmol of the 32P 5’-end-labeled HH363-10 (~ 500 CPM) with 20 pmol of non-labeled HCV 
RNA. Control reactions were performed in the presence of a non-related RNA (RNA 667). 
Digestion reactions were initiated by the addition of RNase T1 (0.1 units), RNase A (0.2 
ng) or Pb2+ acetate (15 mM), and incubated at 4ºC for 2 min, 30 min and 20 min 
respectively. An equal volume of denaturing loading buffer supplemented with EDTA 100 
mM was added, and the products resolved on high resolution denaturing polyacrylamide 
gels (8-20%). These were dried and scanned as above.  
For RNase H-mediated degradation, 50 fmol of the 32P 5’-end-labeled 5’HCV-356 (~ 500 
CPM) were incubated with 20 pmol of non-labeled inhibitor in the presence of 20 pmol of 
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the oligonucleotide asIRES305 (5’-ACTCGCAA-3’) or asIRES196 (5’-TATCCAAGA-3’). 
Complexes were basically formed as described [17]. A final RNase H (USB) concentration 
of 5 U/µl was used to initiate the degradation. Digestion reactions were incubated for 10 
min at 37ºC and stopped on ice. Specific products were resolved on 6% high resolution 
denaturing polyacrylamide gels, dried, and scanned as described above. 
 
Ribosome-IRES complex assembly assays 
The identification of 48S and 80S particles was essentially performed as described by 
Ray et al. [24]. Briefly, a concentration of 40 nM of 32P-internally labeled RNA IRES-FLuc 
(~200,000 dpm) was incubated with 5 µM of the inhibitor RNAs and 5 µl of a translation 
reaction mix containing 4 µl of RRL. To prevent the formation of the 80S particle, the 
translation mix was supplemented with 2 mM of 5’-guanylyl imidophosphate (GMP-PNP, 
Sigma Aldrich). The reactions were incubated at 30ºC for 60 min and stopped on ice. The 
mixtures were then diluted to 150 µl with gradient buffer (20 mM Tris-HCl pH 7.5, 100 
mM KCl, 3 mM MgCl2, 1 mM DTT) and loaded onto a continuous 10-30% linear sucrose 
gradient. Ribosomal complexes were resolved by ultracentrifugation at 30,000 rpm for 4 h 
in a SW40 Ti rotor. Fractions of 500 µl were collected from the top of the gradient and their 
radioactivity was measured using a QuickCount QC-4000/XER Benchtop Radioisotope 
Counter (Bioscan, Inc.).  
 
Transfection of RNA molecules into Huh-7 cells 
Human hepatoma cells (Huh-7) were grown in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) 
and 2 mM of L-glutamine (Sigma), at 37º C in a 5% CO2 atmosphere. Thirty hours before 
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transfection, 120,000 cells were seeded onto a 24-well plate. A mix containing 1 µg of the 
mRNA IRES-FLuc, 0.5 µg of RLuc, 50 µl of Opti-MEM® (Invitrogen) and 1.5 µl of 
transfection reagent (TransFectinTM, Bio-Rad) was complemented with 50 µl of Opti-
MEM®, with or without inhibitor RNA. The amounts of inhibitor employed in these assays 
were established at 0.7, 1.4, 2.7, 4 and 5.4 µg. The total amount of RNA was the same for 
all transfections (7 µg); this was achieved by complementing with a non-related 80 nt long 
RNA molecule (RNA80). RNA molecules were denatured, and then renatured, before 
transfection as above. The lipid-RNA complex was added to the Huh-7 cells and incubated 
for 18 h at 37º C [25]. Firefly and Renilla luciferase activities were determined using the 
Dual-LuciferaseTM reporter assay system (Promega). 
 
RESULTS  
 
In vitro inhibition of IRES-dependent translation by a collection of chimeric RNAs 
We previously described the isolation by in vitro selection of a collection of 30 RNA 
molecules that specifically target the HCV IRES [17]. All the selected variants were 
classified in seven families defined by common sequence motifs. One representative of 
each group was analyzed for its ability of interfering with IRES function in coupled 
transcription-translation systems. A significant inhibitory activity was detected for the 
seven tested molecules [17].  
To further survey the potential IRES-inhibition function of each selected variant and to 
exclude any non-specific effect over transcription, in vitro translation assays of 
monocistronic IRES-FLuc and cap-RLuc mRNAs have been performed using rabbit 
reticulocyte lysates (RRL) in the presence of the different inhibitor RNAs. IRES activity 
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was measured as the synthesis of FLuc protein and compared to the levels of RLuc, which 
is translated in a cap-dependent manner. All the molecules inhibited IRES function at a 
concentration of 5 µM, some of them by as much as 90% (Fig. 2). The difference in the 
experimental approach (translation instead of transcription-translation) might explain the 
apparent discrepancies in the observed inhibition data presented here and those previously 
published [17]. No significant effect was seen on cap-dependent translation (<5%, data not 
shown) for any of the assayed molecules at the concentration tested, indicating a selective 
inhibition of IRES function. Since all the RNA molecules shared the HH363 domain, 
presumably both the targeting site of the aptamer and the structure of the whole inhibitory 
molecule are associated with the potency of each inhibitor.  
 
HH363-10 potently interferes with IRES-dependent translation in vitro 
We focused on HH363-10, which strongly blocked IRES-dependent translation by up to 
90% (Fig. 2). The aptamer sequence contains a motif complementary to the highly 
conserved domain IIIf of the HCV 5’UTR (Fig. 1; [17]), suggesting it to be a possible 
interaction site. This observation led us to study in detail its activity in in vitro translation 
assays. Several concentrations of HH363-10 were tested, ranging from a molar ratio IRES-
FLuc:HH363-10 of 4:1 to 1:125. Strong, dose-dependent inhibition of IRES-dependent 
translation was observed, with an IC50 value of 150 nM (Fig. 3 and Table 1). Further, at the 
lowest concentration of the inhibitor tested, a significant reduction in the FLuc levels was 
achieved (around 20%). This effect was specific for IRES-dependent translation, since the 
synthesis of RLuc protein was not affected even at the highest concentrations assayed 
(<5%, data not shown). To corroborate the specificity of HH363-10 for the HCV IRES, a 
control experiment was performed in which the synthesis of FLuc protein was mediated by 
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the EMCV IRES and normalized with respect to RLuc levels. No significant changes in 
IRES activity were detected in the presence of HH363-10 (Fig. 3), validating its potential 
as a specific HCV IRES inhibitor.  
The contribution of the two activities (cleavage by HH363 and binding by Ap10) to the 
inhibitory capacity of the chimeric molecule was further analyzed. Although they both 
clearly reduced FLuc levels on their own in a dose-dependent manner, their action was 
significantly less than that exerted by the entire HH363-10 molecule at every assayed 
concentration (Fig. 3 and Table 1). A fall in inhibitory activity was also observed (as well 
as a 12-fold increase in the IC50 value) when both HH363 and Ap10 were simultaneously 
added to the translation reaction. This indicates that the combination of the two inhibitory 
domains in a single molecule is required to reach the strongest inhibition.  
 
Cleavage of RNA IRES by HH363-10 
The capacity of HH363-10 for processing IRES RNA was previously in vitro analyzed in 
the absence of any protein factor. A molecule containing the first 691 nucleotides of the 
HCV-1b genome (5’HCV-691; [17]), that comprised the whole IRES to allow ribosome 
assembly and translation [4] was specifically cleaved at the expected site (Romero-López et 
al., unpublished data). We wanted to explore the HH363-10 capacity of processing the 
HCV IRES in the presence of translation factors. For this purpose, a concentration of 40 
nM of the internally radiolabeled 5’HCV-691 RNA was incubated with different amounts 
of HH363-10 in rabbit reticulocytes lysates (RRL), as explained in Materials and methods. 
The proportion of the specific cleavage products increased with increasing amounts of the 
catalytic RNA, showing a concentration-dependent effect (Fig. 4). Cleavage activity was 
compared with the one of HH363. It showed a slight reduction in the amount of the reaction 
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products in comparison to the chimeric inhibitor (Fig. 4). The improvement in the 
processing efficiency of HH363-10 in RRL with respect to HH363 may partially reflect the 
enhancement of the inhibition detected for the chimeric inhibitor. 
 
Identification of the interacting sites between HH363-10 and the IRES region 
We previously identified a sequence within the aptamer, A46UUCGUAA53, 
complementary to the IRES IIIf domain (Fig. 1; [17]), suggesting its involvement in the 
interaction with the IRES. Secondary structure analysis and experimental mapping of the 
residues involved in the interaction was undertaken to validate this hypothesis. 
We firstly proceeded to determine the interacting sequence in the IRES region. For this 
purpose, a 5’-end radiolabeled RNA containing the full 5’UTR was used as a substrate 
(5’HCV-356; [17]).  RNase H probing assays were performed using a 9-mer DNA 
oligonucleotide, asIRES305, complementary to the loop of domain IIIf (see Materials and 
methods). A specific RNase H cleavage product with the expected length was identified 
(305 nt; Fig. 5A). Increasing amounts of HH363-10 promoted a significant and dose-
dependent reduction in the amount of the degradation product (Fig. 5A, C). This indicates 
that domain IIIf is involved in the binding between the chimeric inhibitor and the IRES. No 
effect on the RNase H cleavage pattern was observed when a DNA oligonucleotide 
complementary to positions 196-204 of the HCV genome was used in the presence of 
HH363-10 (asIRES196; Fig. 5B, C), demonstrating the specificity of the interaction.  
RNase and lead probing assays were subsequently performed to analyze the secondary 
structure of HH363-10 and to identify the residues involved in the association to domain 
IIIf. The inhibitor RNA was 5’ end-labeled with 32P and incubated with a molar excess of a 
non-related RNA (RNA 667). Partial digestion with nucleases (RNase T1 and RNase A) 
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and lead was subsequently performed. Cleavage mainly occurred at specific single stranded 
positions (G nucleotides for RNase T1 probing, C or U residues for RNase A reactions and 
any nucleotide for lead treatments). The degradation pattern of HH363-10 was used for 
secondary structure predictions using Mfold software [26]. This showed the exposure of 
nucleotides A46UUCGUAA53 in an apical loop (Fig. 1B, Fig. 6). Further in silico structural 
analyses with the PknotsRG program predicted the formation of an intramolecular 
pseudoknot involving the nucleotides A46 to G50 and C63 to U67 (Fig. 1B, Fig. 6). 
The results were compared with those in the presence of the IRES to map the residues 
involved in the interaction. RNA 5’HCV-691gg was used as a substrate. This extends to 
nucleotide 691 of the HCV-1b genome sequence, but contains two substitutions (U362?G 
and C363?G) that completely abolish cleavage by the catalytic domain HH363 [27, 28]. 
The results showed nucleotides G45 to C49 to be now clearly resistant to cleavage (Fig. 6), 
suggesting their involvement in the interaction of HH363-10 with the IRES. Further, 
residues C63 to U67 showed greater sensitivity to the hydrolytic reagents in the presence of 
the substrate 5’HCV-691gg. This was in good agreement with the formation of an 
intramolecular pseudoknot structure in the inhibitor. 
These results confirm the initial hypothesis that the IIIf domain is the interaction site for 
HH363-10. To our knowledge, this is the first report describing an RNA aptamer targeting 
the HCV IRES pseudoknot motif. 
 
HH363-10 prevents the assembly of the 80S ribosomal complex 
Domain IIIf of HCV IRES has been suggested a crucial motif for the recruitment of the 
40S ribosomal subunit in the formation of the 48S particle. It is also reported to be involved 
in the subsequent structural RNA IRES rearrangements that finally lead to the formation of 
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an active 80S translational complex [19, 29, 30]. The effect of HH363-10 on HCV IRES-
mediated ribosome assembly was therefore examined. For this purpose, in vitro translation 
reactions containing 32P-labeled mRNA IRES-FLuc were performed either in the presence 
or absence of a 125-fold molar excess of HH363-10. The 48S and 80S particles were 
analyzed by sucrose density gradient ultracentrifugation (see Materials and methods). After 
fractioning, they were detected as two different and well-defined peaks when no inhibitor 
was added (Fig. 7). Experimental conditions were established to achieve the reproducibility 
in the efficiency of the complexes 48S and 80S formation in the absence of inhibitor. The 
addition of HH363-10 reduced the formation of the 80S complex, whereas the 48S particle 
was clearly produced (Fig. 7). These data were confirmed in a subsequent independent 
assay (data not shown). A similar result was obtained when reactions were incubated with 
GMP-PNP, a non-hydrolysable GTP analog that blocks the progression of a translation 
initiation complex at the 48S particle stage (Fig. 7). Similarly, an evident reduction in 80S 
complex accumulation was detected in the presence of Ap10 (Fig. 7), while no significant 
changes were observed when HH363 was present (Fig. 7). These observations suggest that 
the prevention of 80S particle formation is related to the inhibition exerted by HH363-10 
and Ap10; this inhibition is explained by their binding to the IIIf domain. 
 
Inhibition of IRES function by HH363-10 in a human liver cell line  
The effect of HH363-10 on IRES function in cell culture was also examined. A mixture 
of the IRES-FLuc and cap-RLuc transcripts was co-transfected with HH363-10 into a 
hepatocellular carcinoma cell line (Huh-7) that supports efficient HCV replication. A dose-
dependent study was performed to determine the activity of the inhibitor. HH363-10 
appeared as an effective and specific inhibitor of IRES-dependent translation, reducing 
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FLuc activity by up to 50% at 300 nM (Fig. 8) without affecting to that shown by RLuc 
(<5%; data not shown).  
Since the strongest inhibitory effect resides in the complete molecule, a collection of 
mutants was constructed to further study the contribution of the cleavage and binding 
activities to the inhibitory function of HH363-10 (Fig. 1B). This included a catalytically 
non-active derivative (HH363m-10), a null variant for the interaction site in the aptamer 
(HH363-10m), and a completely inactive molecule containing both modifications 
(HH363m-10m; Fig. 1B). These mutations involve a small number of changes in the 
nucleotidic sequence, but they entail a complete loss of function. Modifications in the 
catalytic core led to a full loss of cleavage activity and mutations in the aptamer domain 
completely abolished association with the IRES (data not shown). Inhibition assays showed 
that functionality in cells was also severely affected by these mutations. Single mutants 
mildly inhibited IRES-dependent translation, whereas no inhibitory effect was observed for 
the HH363m-10m construct. This result suggests that the strongest inhibitory activity is an 
intrinsic feature of the entire HH363-10 molecule combining both activities. 
 
DISCUSSION 
 
The search of novel therapeutic strategies to fight against HCV infection is a major goal. 
The high variation rate of the viral genome leads to the appearance of populations 
consisting of a spectrum of genomic sequences, in which resistant variants to treatment 
emerge and contribute to the progression of the disease [1]. In recent years, this has been 
outlined as the main difficulty to achieve effective therapies and has imposed the necessity 
of searching new targets. Classical medical approaches targeting essential HCV proteins 
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were considered excellent strategies for a long time. However, mutations conferring 
resistance to the treatment were finally reported [31]. Efforts were subsequently focused on 
interfering with highly conserved genomic regions. The great advances in the antisense and 
siRNA technology prompted the idea of an efficacious therapy in the near future, but in 
many cases the emergence of resistant viral genomes was certainly observed for this and 
other viral infections [9-13]. One of the most promising approaches is the specific 
recognition of highly structured regions in the genomic RNA that retain an important 
sequence and structure conservation rate and fulfill essential roles in viral translation and 
replication. They interact with viral and host proteins to carry out these crucial functions 
for the viral maintenance and propagation. This means that the assessment of both primary 
and secondary structure in those RNA domains is crucial for the conservation of the 
function [18]. It has been shown that mutations that preserve the secondary structure also 
result in a drastic reduction of the in vitro translation efficiency [18]. This is in good 
agreement with the high sequence conservation observed in this domain among different 
HCV isolates [32]. In this context, targeting the HCV IRES region is an excellent 
therapeutic option. The use of ribozymes and aptamers as anti-HCV agents has been 
extensively reported [8]. Aptamers are considered an excellent option to target highly 
folded RNA domains [33-35]. In contrast to antisense, which interaction with complex 
structured domains is severely restricted, aptamers only require a short stretch of 
complementary nucleotides in an appropriate structural context to exhibit the highest 
affinity and efficiency. Further, the development of combination therapies using antiviral 
compounds with different specificities would additionally contribute to prevent the 
emergence of resistant viral pools [1, 14, 15]. The functional characterization of HH363-10, 
which simultaneously targets two highly conserved regions that are required for the 
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preservation of the IRES activity [18, 36, 37], clearly shows the advantage of combining 
two inhibitory activities in a single molecule to achieve the strongest effect and allows the 
proposal of our strategy as an excellent start point for the development of new therapeutic 
tools.  
The chimeric RNA HH363-10 strongly inhibited HCV IRES-dependent translation in 
vitro, with an IC50 of 150 nM. This value is considerably lower than those reported for a 
decoy RNA of the stem-loop IIIe-f and for two aptamers of the IRES targeting domains II 
and IIId [24, 33, 35] but slightly higher than other obtained for an antisense RNA of the 
IIId domain [25]. Since HH363-10 combines two inhibitory activities targeting different 
domains of the HCV genome, it might result in a more effective anti-HCV agent, though 
this would require further analysis. 
HH363-10 also showed inhibitory activity of the HCV IRES function in a hepatoma cell 
line, though to a less extent that in vitro. This discrepancy has been previously reported 
[24]. Ray and Das described differences in the inhibition of HCV IRES exerted by small 
RNAs between in vitro and in cell culture experiments. Further, they reported different 
inhibition levels in two cell lines, Hela and Huh-7, under similar experimental conditions. 
It has also been shown that HCV-IRES activity is dependent on the concentration of 
different translation trans-acting factors. Salt concentrations and the cell cycle phase may 
influence the HCV-IRES efficiency [38-40]. Differences in inhibition levels can also be the 
result of the different concentrations of RNA at the right cellular compartment compared to 
the in vitro experiments. 
It is noteworthy that the activity of the entire molecule is significantly more potent than 
that measured for the components as independent molecules, HH363 and Ap10. This is 
consistent with the fact that Ap10 was isolated by the in vitro selection process attached to 
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HH363. This, together with the fact that mutations that block either the catalytic activity of 
the hammerhead ribozyme or the association via the aptamer domain negatively affect the 
inhibitory capacity of HH363-10, highlight the need for the selected full-length molecule 
conserving both inhibitory activities if maximum inhibition is to be attained. Although only 
a low proportion of specific cleavage products are generated by the HH363-10 in RRL, the 
abolishment of the catalytic activity negatively influences the inhibitory properties of 
HH363-10, meaning that it contributes to the global inhibitory effect, though to a low 
extent. Besides the cleavage activity, we cannot discard a possible antisense effect of the 
catalytic domain. It is also likely that a structural stabilization of the aptamer domain is 
mediated by the HH363 motif. An improvement in the access to the domain IIIf is feasible 
too. We suggest that the binding of HH363-10 to its target is the key step in its mechanism 
of action, and that the recognition of the primary, secondary and tertiary structure in the 
substrate is the essential point to achieve the effectiveness of the inhibitor. None of these 
possibilities can be ruled out; neither are they mutually exclusive. Other explanations may 
also be possible. We argue that observed inhibition is an intrinsic property of HH363-10 
and we cannot define the exact contribution of each activity. It should be also noted that the 
combination of both inhibitory activities may contribute to reduce the chance of appearance 
of resistant viral pools.  
The results show that domain IIIf of the HCV IRES is involved in the interaction with 
HH363-10 (Fig. 5). To our knowledge, this is the first report describing an RNA aptamer 
that specifically interacts with the pseudoknot structure of the HCV IRES. We have not any 
information about the nature of this interaction. Nucleotides involved in the association 
between the inhibitor and the substrate map in apical loops (Fig. 5, Fig. 6). It would be 
therefore plausible that tertiary restricted kissing interactions are established. Since domain 
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IIIf participates in the formation of a pseudoknot structure, it seems likely that an additional 
contribution is required to destabilize this motif and promote the kissing between HH363-
10 and the IRES. We hypothesize that residues G41A42G43, complementary to positions 325 
to 327 at the 3’end of the pseudoknot structure in the IRES, are working in that way. This is 
supported by the fact that they show a decrease in their sensitivity to RNases mediated 
cleavage in the presence of the substrate RNA (Fig. 6). From a structural and functional 
point of view, these results are of clear interest. Domain IIIf shows strong sequence and 
structure conservation among different isolates and has an important role in IRES function 
[18-20]. It has been described that distortions in its architecture dramatically affect viral 
polyprotein translation [18]. All these features make it an excellent target for HCV 
inactivation assays. The present data show that, as a result of the association of HH363-10 
to IRES through the IIIf domain, the formation of the 80S particle in vitro is almost 
completely abolished (Fig. 7), which may explain the inhibitory activity of HH363-10.  
In summary, the combination of antiviral agents with different specificity and activity in 
a sole molecule is a novel strategy that could provide a good way of restraining the 
emergence of resistant variants and may be extended to other viral infections, such as HIV. 
The anti-IRES properties shown by HH363-10 both in vitro and in cell culture call for its 
mechanism of action and activity in viral culture systems to be thoroughly investigated. 
Work in this area is currently underway at our laboratory. Finally, this chimeric molecule 
has potential as a biochemical tool for studying RNA-RNA interactions and investigating 
the role of the pseudoknot structure in the HCV cycle.   
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TABLE 1 
 
IC50 values for the different inhibitory RNAs 
Inhibitor IC50 (µM)a Relative FLuc Synthesisb 
HH363-10 0.15 ± 0.04 11.22 ± 2.77 
Ap10 1.95 ± 0.25 30.76 ± 11.60 
HH363 3.46 ± 0.32 42.22 ± 6.32 
HH363+Ap10 1.75 ± 0.41 32.39 ± 5.31 
 
a IC50 values were derived from the equation y = 100/(1 + 10(LogIC50-X)).  
b Data correspond to the highest concentration of inhibitor tested. Values are the mean of 
at least three independent trials.  
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FIGURE LEGENDS 
 
Figure 1. The HCV-IRES domain and HH363-10. A) Sequence and secondary structure of 
the HCV IRES. The cleavage site is indicated by an arrow. Nucleotides proposed to interact 
with HH363-10 are shown in bold and enlarged. Start codon is in italics. B) Sequence and 
secondary structure of HH363-10 predicted by experimental constraints and employing 
MFold software. Ribozyme HH363 is shadowed. Tertiary contacts predicted by PknotsRG 
are indicated by dotted lines. G nucleotides accessible to T1 under non-denaturing 
conditions are indicated by open (low), gray (medium) or filled triangles (high 
accessibility). Residues in the aptamer domain responsible for the interaction with domain 
IIIf of the IRES are shown in bold and enlarged. Encircled nucleotides were mutated as 
indicated to generate the respective inactive variants (HH363m-10, G14 ? A; HH363-10m, 
C49GUA52 ? GCAC; HH363m-10m, G14 ? A and C49GUA52 ? GCAC). 
 
Figure 2. In vitro inhibition of IRES-dependent translation by the selected variants. The 
bar chart shows the reduction in FLuc synthesis achieved for each inhibitor RNA at a 
concentration of 5 µM, normalized with respect to the cap-dependent translation of RLuc 
mRNA. Values are referred to those obtained in the absence of inhibitor, and are the mean 
of at least three independent assays. 
 
Figure 3. Specific in vitro inhibition of IRES function by HH363-10. The plot shows the 
reduction in FLuc synthesis normalized with the levels of RLuc protein. The IRES activity 
obtained at each concentration of inhibitor is represented as the percentage of the control 
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reaction in the absence of HH363-10. Data were fitted to a non-linear regression curve to 
determine the IC50 value and are the mean of four independent experiments. 
 
Figure 4. Cleavage of IRES RNA in RRL. The graph shows the fraction of the internally 
radiolabeled 5’HCV-691 RNA substrate processed by different concentrations of either 
HH363-10 (open circles) or HH363 (filled circles) in the presence of rabbit reticulocyte 
lysate.  
 
Figure 5. Probing assays of the IRES/HH363-10 complex. A) and B) show 
autoradiographs of the RNase H probing assays for 5’HCV-356 with the oligonucleotide 
asIRES305 (A) or asIRES196 (B). An amount of 50 fmol of the 32P 5’ end-labeled 
substrate was incubated with (+) or without HH363-10 in the presence of the probe 
oligonucleotide. Digestion reactions were initiated by the addition of 15 U of RNase H and 
extended up to 10 min. Specific cleavage products were resolved on a 6% high resolution 
denaturing polyacrilamide gel and are indicated by an arrow. T1L, T1 cleavage ladder. C) 
The fraction of RNase H cleavage product at different concentrations of HH363-10 is 
represented.  
 
Figure 6. Secondary structure analysis of HH363-10 and identification of the interacting 
residues with the IRES. A) 32P 5’ end-labeled HH363-10 was partially digested with RNase 
T1, RNase A or Pb2+, either in the absence (-) or presence (+) of the substrate RNA 
5’HCV-691gg. The right panel shows a more detailed view of the cleavage pattern for the 
aptamer domain. Residues participating in the pseudoknot structure are indicated by an 
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asterisk. The arrows show nucleotides G41AG43. T1L, T1 cleavage ladder. OH, alkaline 
ladder.  
 
Figure 7. HH363-10 and Ap10 prevent the assembly of the 80S ribosomal particle. Sucrose 
gradient sedimentation profiles of 32P-internally labeled IRES-FLuc mRNA incubated in 
RRL in the absence and presence of a 125-fold molar excess of inhibitor RNAs (HH363-
10, Ap 10 or HH363) or 2 mM of GMP-PNP. Filled circles, control reaction profile; open 
circles, sedimentation profile with the inhibitor. In all cases, the percentage disintegrations 
are represented against the corresponding gradient fraction number. The 48S and 80S 
complexes are indicated. Fractions were collected from the top downwards.  
 
Figure 8. Inhibition of IRES-dependent translation by HH363-10 in Huh-7 cells. Huh-7 
cells were co-transfected with different amounts of inhibitor RNAs and 1.5 µg of a mix 
containing the transcripts IRES-FLuc and RLuc. The collection of mutants was obtained by 
the introduction of variations in HH363-10 nucleotidic sequence as indicated in figure 1. 
IRES function is measured as the activity of FLuc protein and referred to that obtained for 
RLuc. Luciferase activity in the control reactions is established as 100%. Data points are 
the mean of three independent experiments.  
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Figure 3  
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7
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Figure 8 
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